Celanese Announces Grant Award to Develop Long-Acting, Refillable Drug Delivery Solution

Aug 24, 2022

Celanese today announced receipt of a grant from the Bill & Melinda Gates Foundation to produce and characterize a working prototype for a refillable contraceptive implant. The research and development will be conducted within the Celanese Pharmaceutical Development and Feasibility Lab and the project is expected to produce a functional prototype that meets all established project parameters within an 18-month timeframe.

The development of a refillable contraceptive implant has the potential to benefit women in low- and middle-income countries who presently either do not have access to modern contraceptive options or could benefit from the flexibility and control of the contraception this product design affords. Through this grant, Celanese will be providing critical research and development activities intended to facilitate and accelerate access to long-acting contraceptive options.

“We have a long history working in the area of women’s health and are honored by the trust placed in our team through this grant from the Gates Foundation,” said Laura Brand, vice president of the Celanese medical and pharmaceutical business. “The project concept is based on our VitalDose® drug delivery platform, a controlled release technology with decades of commercial use in the U.S. and Europe. We are proud to be part of this opportunity to expand access to solutions for women’s health to many more women globally.”

Celanese offers cutting-edge medical and pharmaceutical material solutions and expert development support to pharmaceutical and medical device companies worldwide. With more than 40 years of experience supporting key applications and the demanding requirements of healthcare, Celanese continues to invest in this area, including by finding new ways to deliver a sustained dose of medication over time. The company’s expanding portfolio includes solutions and technologies for applications across drug delivery, medical devices, orthopedics, advanced surgical instruments and connected devices.

For more information on Celanese VitalDose technology, visit www.vitaldose.com.

View Report
View Index
Celanese ESG Index 2021/2022

This website uses 'cookies' to give you the best, most relevant experience. Using this website means you are Ok with this. You can change which cookies are set at any time - and find out more about them - by following this link.

Information on the processing of your personal data within the USA by Google and Marketo:
By clicking "Accept All", or selecting "Marketing" and/or "Analytical" and then clicking "Accept Selected", you also consent in accordance with Art. 49(1)(a) GDPR that your data may be processed in the USA. The USA is considered by the European Court of Justice to be a country with no adequate level of data protection according to EU standards. In particular, there is a risk that your data may be processed by US authorities for surveillance and investigation purposes, possibly without the opportunity for legal remedies. If you select “Necessary” and then click on "Accept Selected”, the transfer described above will not take place. You will find more detailed information in our privacy policy.